The Effect of Plan Type and Comprehensive Medication Reviews on High-Risk Medication Use
- PMID: 29694292
- PMCID: PMC10397681
- DOI: 10.18553/jmcp.2018.24.5.416
The Effect of Plan Type and Comprehensive Medication Reviews on High-Risk Medication Use
Abstract
Background: In 2007, the Centers for Medicare & Medicaid Services (CMS) instituted a star rating system using performance outcome measures to assess Medicare Advantage Prescription Drug (MAPD) and Prescription Drug Plan (PDP) providers.
Objective: To assess the relationship between 2 performance outcome measures for Medicare insurance providers, comprehensive medication reviews (CMRs), and high-risk medication use.
Methods: This cross-sectional study included Medicare Part C and Part D performance data from the 2014 and 2015 calendar years. Performance data were downloaded per Medicare contract from the CMS. We matched Medicare insurance provider performance data with the enrollment data of each contract. Mann Whitney U and Spearman rho tests and a hierarchical linear regression model assessed the relationship between provider characteristics, high-risk medication use, and CMR completion rate outcome measures.
Results: In 2014, an inverse correlation between CMR completion rate and high-risk medication use was identified among MAPD plan providers. This relationship was further strengthened in 2015. No correlation was detected between the CMR completion rate and high-risk medication use among PDP plan providers in either year. A multivariate regression found an inverse association with high-risk medication use among MAPD plan providers in comparison with PDP plan providers in 2014 (beta = -0.358, P < 0.001) and 2015 (beta = -0.350, P < 0.001), the CMR completion rate in 2015 (beta = -0.221, P < 0.001), and enrollee population size in 2015 (beta = -0.203, P = 0.001).
Conclusions: This study found that MAPD plan providers and higher CMR completion rates were associated with lower use of high-risk medications among beneficiaries.
Disclosures: No outside funding supported this study. Silva Almodovar reports a fellowship funded by SinfoniaRx, Tucson, Arizona, during the time of this study. The other authors have nothing to disclose.
Conflict of interest statement
No outside funding supported this study. Silva Almodovar reports a fellowship funded by SinfoniaRx, Tucson, Arizona, during the time of this study. The other authors have nothing to disclose.
References
-
- Academy of Managed Care Pharmacy, American Pharmacists Association . Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality. J Am Pharm Assoc (2003). 2014;54(3):228-40. - PubMed
-
- Centers for Medicare & Medicaid . Fact sheet - 2017 star ratings. In: 2017 star rating and display measures. 2017. Available at: https://www.cms.gov/medicare/prescription-drug-coverage/prescriptiondrug.... Accessed March 31, 2018.
-
- Centers for Medicare & Medicaid Services . Medicare 2016 Part C & D star rating technical notes. In: 2016 star ratings and display measures. March 24, 2017. Available at: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrug.... Accessed March 31, 2018.
-
- Centers for Medicare & Medicaid Services . Medicare 2017 Part C & D star rating technical notes. In: 2017 star rating and display measures. March 24, 2017. Available at: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrug.... Accessed March 31, 2018.
-
- Centers for Medicare & Medicaid Services . Announcement of calendar year (CY) 2017 Medicare Advantage capitation rates and Medicare Advantage and Part D payment policies and final call letter. April 24, 2016. Available at: https://www.cms.gov/Medicare/Health-Plans/MedicareAdvtgSpecRateStats/Dow.... Accessed March 31, 2018.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
